END DM1
Research type
Research Study
Full title
Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1)
IRAS ID
282941
Contact name
Chris Turner
Contact email
Sponsor organisation
Virginia Commonwealth University
Clinicaltrials.gov Identifier
Duration of Study in the UK
4 years, 11 months, 30 days
Research summary
The overall goal of this study is to expedite the development of new therapies for DM1 by validating new clinical assessments for measuring disease status and to collect data and biological samples to help understand disease progression and severity. This will provide valuable information and material to further research into DM1, develop new therapies and inform future design of new drug trials. As such, during the conduct of this study and after its completion, de-identified, raw, unanalyzed data and biological samples may be provided to researchers or drug companies pursuing therapeutics for DM1, but it will not be used for any marketing purposes.
REC name
London - South East Research Ethics Committee
REC reference
22/LO/0032
Date of REC Opinion
22 Feb 2022
REC opinion
Further Information Favourable Opinion